Health-care shares tumbled Wednesday, making it the worst performing of the S&P 500 Index’s ten sectors, as pricing issues in the industry flared up again, first inflamed by an astronomical price hike of a cancer drug by then-Turing Pharmaceuticals CEO Martin Shkreli. The sector declined 1.7%, compared with a 0.7% slip in the broader index. Shares of Mylan dropped 6% on continuing controversy over the company’s EpiPen pricing. On the Dow Jones Industrial Average, UnitedHealth Group Inc. and Merck Inc. were the worst performers. Meanwhile, the iShares Nasdaq Biotechnology ETF fell 3.5%.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News